Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons

[1]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[2]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[3]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[4]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[5]  N. Hattori,et al.  Parkin is linked to the ubiquitin pathway , 2001, Journal of Molecular Medicine.

[6]  T. Aw,et al.  Gadd153 Sensitizes Cells to Endoplasmic Reticulum Stress by Down-Regulating Bcl2 and Perturbing the Cellular Redox State , 2001, Molecular and Cellular Biology.

[7]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[8]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Heller,et al.  Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system , 2000, Brain Research.

[10]  S. Milstien,et al.  Preferential Resistance of Dopaminergic Neurons to the Toxicity of Glutathione Depletion Is Independent of Cellular Glutathione Peroxidase and Is Mediated by Tetrahydrobiopterin , 2000, Journal of neurochemistry.

[11]  Q. Dou,et al.  Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[13]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[14]  K D Wilkinson,et al.  Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. , 1998, Biochemistry.

[15]  Hidefumi Ito,et al.  Immunocytochemical Co‐localization of the Proteasome in Ubiquitinated Structures in Neurodegenerative Diseases and the Elderly , 1997, Journal of neuropathology and experimental neurology.

[16]  E. Grasbon-Frodl,et al.  Lazaroid Treatment Prevents Death of Cultured Rat Embryonic Mesencephalic Neurons Following Glutathione Depletion , 1996, Journal of neurochemistry.

[17]  Annette M. Schmid,et al.  Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.

[18]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[19]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[20]  C. Marsden,et al.  Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration , 2005, Journal of Neural Transmission.